PBYI Q2 2024 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$311M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$47M-13.7% YoY

Gross Profit

$36M77.4% margin

Operating Income

-$2M-4.6% margin

Net Income

-$5M-9.6% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

+7.6%

Cash Flow

Operating Cash Flow

$1M

Free Cash Flow

$1M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$205M

Total Liabilities

$156M

Stockholders' Equity

$49M

Cash & Equivalents

$67M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$47M	$55M	-13.7%
Gross Profit	$36M	$43M	-14.7%
Operating Income	-$2M	$5M	-144.5%
Net Income	-$5M	$2M	-313.0%

Revenue Segments

Product

$44M94%

Royalty

$3M6%